Bradmer open to mergers following CRO setback
This article was originally published in Scrip
Executive Summary
Bradmer Pharmaceuticals will consider a merger after its board of directors recommended a strategic review following "logistic issues" with an unnamed contract research organisation, it has told Scrip.